SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Biotechnology

Healthcare
$29.68 +2.49%

+$0.45 today

Market cap
$993.14M
Beta
-0.34
P/E (TTM)
-14.1
EPS (TTM)
-$1.32
52W Low $17.06High $32.44

Volume 0.10M

Average 0.09M

SGP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

SpyGlass Pharma, Inc. Common StockNASDAQ: SGP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development of $8.24M in Q1 FY2026

Q1 FY2026 research & development was $8.24M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.24M+7.0% QoQ
Last fiscal yearDec 2025
$28.64M— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
28.64M USD
Year-over-year change
—

Research & Development vs competitors

How SGP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
SGP Competitors
Research & Development for SGP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALCAlcon Inc.LTM Sep 2026$1.44B USD+51.4%+12.1%13.1%
BLCOBausch + Lomb CorporationLTM Jun 2026$404M USD+12.5%+6.5%7.6%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$234.61M USD+45.4%+64.5%3080.9%
OCULOcular Therapeutix, Inc.LTM Mar 2026$220.45M USD+47.2%+54.5%423.6%
GKOSGlaukos CorporationLTM Jun 2026$177.17M USD+26.4%+6.9%28.9%
OCSOculis Holding AGLTM Mar 2026CHF 56.48M CHF+0.9%+34.9%11206.4%
STAASTAAR Surgical CompanyLTM Apr 2026$38.43M USD-26.2%+3.6%13.2%
RXSTRxSight, Inc.LTM Mar 2026$37.65M USD+2.6%+14.1%29.5%
SGPSpyGlass Pharma, Inc. Common StockFY2025$28.64M USD———
SGHTSight Sciences, Inc.LTM Mar 2026$12.72M USD-28.5%-13.9%16.0%
Peer median (excluding SGP) —+12.5%+12.1%28.9%

Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.